It is designed to be of interest to cancer scientists and medical oncologists with expertise in basic, translational and clinical research.

Its objective is to cover recent and exciting developments in the field that are crucial to our understanding of the multifaceted role of the DNA damage response and associated tumour cell specific alterations in cancer initiation, progression and precision cancer therapy.

It is an exciting and rapidly evolving research field that will expedite the development and implementation of biomarkers for patient stratification and of novel treatment concepts in precision cancer medicine.

Topics to be covered

• Mechanistic insights into the cellular responses to DNA damage and genomic stability
• Therapeutic exploitation of defective DNA damage response and repair
• New treatment approaches combining radiotherapy with targeted drugs or immunotherapy
• Radiobiology biomarkers for precision radiotherapy